HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Day One Biopharmaceutical (NASDAQ:DAWN) and maintained a $40 price target.
August 01, 2024 | 10:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Day One Biopharmaceutical and maintained a $40 price target, indicating continued confidence in the company's growth prospects.
The reiteration of a Buy rating and maintenance of a $40 price target by HC Wainwright & Co. suggests strong confidence in Day One Biopharmaceutical's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100